Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.
The first is an oral presentation at the 62nd Society of Reproductive Investigation conference, March 25-28, Hilton San Francisco, CA. Professor Mor's presentation will focus on the pre-clinical efficacy studies that justified the Company's decision to progress Cantrixil into the clinic for the treatment of abdominal carcinomatosis.
The second is a late-breaking poster at the annual American Association for Cancer Research (AACR) conference, April 18-22, Pennsylvania Convention Center, Philadelphia, PA. The presentation will review mechanistic aspects of Cantrixil efficacy in ovarian cancer stem cells, and also detail in vivo data generated on Cantrixil in Yale's recurrent ovarian cancer carcinomatosis model that has informed the design of the Company's first-in-man clinical trial.
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery